IVERIC bio, Inc. (ISEE): Price and Financial Metrics
GET POWR RATINGS... FREE!
ISEE Stock Price Chart Interactive Chart >
ISEE Price/Volume Stats
| Current price | $10.44 | 52-week high | $19.34 |
| Prev. close | $9.97 | 52-week low | $5.96 |
| Day low | $9.90 | Volume | 6,244,900 |
| Day high | $10.47 | Avg. volume | 1,754,928 |
| 50-day MA | $11.95 | Dividend yield | N/A |
| 200-day MA | $14.76 | Market Cap | 1.22B |
IVERIC bio, Inc. (ISEE) Company Bio
IVERIC bio, Inc. (formerly Ophthotech Corporation) is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). The company was founded in 2007 and is based in New York, New York.
Latest ISEE News From Around the Web
Below are the latest news stories about IVERIC bio Inc that investors may wish to consider to help them evaluate ISEE as an investment opportunity.
IVERIC bio, Inc. (ISEE) Q4 2021 Earnings Call TranscriptRepresenting IVERIC bio today are Mr. Glenn Sblendorio, chief executive officer; Dr. Pravin Dugel, president; Mr. And we are pleased to welcome Mr. Tony Gibney as chief business and strategy officer. |
Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial ResultsPARSIPPANY, N.J., February 24, 2022--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2021 and provided a general business update. |
Iveric Bio to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022NEW YORK, February 17, 2022--Iveric Bio announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, February 24, 2022. |
Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapitalIn this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. You can skip our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, and go directly to the Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Dr. Srinivas Akkaraju […] |
Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic AtrophyNEW YORK, February 11, 2022--Iveric Bio announced a post-hoc analysis from the GATHER1 Zimura Phase 3 clinical trial, which evaluated various GA growth parameters. |
ISEE Price Returns
| 1-mo | -5.09% |
| 3-mo | -31.04% |
| 6-mo | -34.75% |
| 1-year | 71.43% |
| 3-year | 762.81% |
| 5-year | 286.67% |
| YTD | -37.56% |
| 2021 | 141.97% |
| 2020 | -19.46% |
| 2019 | 615.00% |
| 2018 | -61.54% |
| 2017 | -35.40% |
Loading social stream, please wait...